KR20140041553A - 2형 당뇨병의 치료에 사용하기 위한 약제학적 병용물 - Google Patents

2형 당뇨병의 치료에 사용하기 위한 약제학적 병용물 Download PDF

Info

Publication number
KR20140041553A
KR20140041553A KR1020137033311A KR20137033311A KR20140041553A KR 20140041553 A KR20140041553 A KR 20140041553A KR 1020137033311 A KR1020137033311 A KR 1020137033311A KR 20137033311 A KR20137033311 A KR 20137033311A KR 20140041553 A KR20140041553 A KR 20140041553A
Authority
KR
South Korea
Prior art keywords
patients
treatment
subject
pharmaceutical combination
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137033311A
Other languages
English (en)
Korean (ko)
Inventor
루이즈 실베스트르
가보르 보카
파트릭 미오섹
Original Assignee
사노피-아벤티스 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 도이칠란트 게엠베하 filed Critical 사노피-아벤티스 도이칠란트 게엠베하
Publication of KR20140041553A publication Critical patent/KR20140041553A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020137033311A 2011-05-13 2012-05-11 2형 당뇨병의 치료에 사용하기 위한 약제학적 병용물 Ceased KR20140041553A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166052.8 2011-05-13
EP11166052 2011-05-13
PCT/EP2012/058779 WO2012156312A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in the treatment of diabetes type 2

Publications (1)

Publication Number Publication Date
KR20140041553A true KR20140041553A (ko) 2014-04-04

Family

ID=46052773

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033311A Ceased KR20140041553A (ko) 2011-05-13 2012-05-11 2형 당뇨병의 치료에 사용하기 위한 약제학적 병용물

Country Status (12)

Country Link
US (1) US20130040878A1 (OSRAM)
EP (1) EP2709652A1 (OSRAM)
JP (1) JP6005140B2 (OSRAM)
KR (1) KR20140041553A (OSRAM)
CN (2) CN109045283A (OSRAM)
AR (1) AR086356A1 (OSRAM)
AU (1) AU2012257780B2 (OSRAM)
BR (1) BR112013029256A8 (OSRAM)
CA (1) CA2835336A1 (OSRAM)
MX (1) MX356728B (OSRAM)
RU (2) RU2017129878A (OSRAM)
WO (1) WO2012156312A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX366685B (es) * 2013-01-17 2019-07-19 Vtv Therapeutics Llc Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US12421245B2 (en) 2020-04-01 2025-09-23 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
EP2324853B1 (en) * 2009-11-13 2015-08-26 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法

Also Published As

Publication number Publication date
BR112013029256A8 (pt) 2018-01-16
MX2013013198A (es) 2014-02-20
MX356728B (es) 2018-06-12
WO2012156312A1 (en) 2012-11-22
US20130040878A1 (en) 2013-02-14
RU2013155480A (ru) 2015-06-20
CN103648519A (zh) 2014-03-19
JP6005140B2 (ja) 2016-10-12
RU2017129878A (ru) 2019-02-05
CN109045283A (zh) 2018-12-21
AU2012257780B2 (en) 2017-06-01
EP2709652A1 (en) 2014-03-26
AR086356A1 (es) 2013-12-04
BR112013029256A2 (pt) 2016-11-29
JP2014518860A (ja) 2014-08-07
CA2835336A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
KR20140041553A (ko) 2형 당뇨병의 치료에 사용하기 위한 약제학적 병용물
KR101983982B1 (ko) 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
US20220054594A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6410604B2 (ja) ２型糖尿病における基礎インスリンに対する上乗せ療法としてのリキシセナチド
KR20140043756A (ko) 2형 당뇨병 환자에서 체중 감소를 유도하고/하거나 2형 당뇨병 환자에서 체중 증가를 예방하는데 사용하기 위한 약제학적 병용물
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
CN107693782A (zh) 用于治疗2型糖尿病患者的利西拉来和二甲双胍
CN107693783A (zh) 2型糖尿病的治疗方案
CN107375909A (zh) 在2型糖尿病患者中预防低血糖症
EP3268029B1 (en) Treatment of type 2 diabetes mellitus patients
CN116867505A (zh) 替西帕肽治疗方法
McFarlane Antidiabetic medications and weight gain: implications for the practicing physician
TW201311268A (zh) 用於治療第２型糖尿病病患之醫藥組成物
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
TW201311270A (zh) 用於改善血糖控制作為基礎胰島素附加治療之醫藥組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170410

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180404

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181011

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180404

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181011

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180604

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170410

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181210

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20181011

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180604

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180404

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170410